Épisodes

  • Summary of Key Concepts

    Summary of Key Concepts
    Jul 31 2025
    • Subcutaneous ICI products may offer significant time savings for patients, caregivers, and health care facilities with shorter compounding, administration, and chair time
    • With multiple ICI therapies now approved for subcutaneous injection and more under development, it is vital for institutions to develop interprofessional/multidisciplinary approaches and workflows to integrate novel therapies


    Voir plus Voir moins
    8 min
  • Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems

    Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems
    Jul 31 2025
    • SC products offer convenient and safe options for patients that may be preferred by patients
    • Effective communication among interprofessional, multidisciplinary team and patients/caregivers is crucial to success and streamlining processes
    • Training is required for providers and staff related to operational, clinical, and financial considerations of SC products
    Voir plus Voir moins
    23 min
  • Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)

    Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
    Jul 30 2025
    • Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)
    • Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapies
    • Patients receiving SC ICI may experience mild injection site reactions
    • Clinical guidelines (NCCN) recommend
    Voir plus Voir moins
    8 min
  • Background of ICI & Highlights in Oncology

    Background of ICI & Highlights in Oncology
    Jul 30 2025
    • Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 years
    • Multiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011
    • Robust survival benefit seen with ICI across multiple tumor types
    • IV ICI therapy requires line access and creates increased chair time
    • Subcutaneous (SC) ICI options provide increased patient convenience and operational efficiencies
    • SC products may increase nurse resources due to time spent administering
    Voir plus Voir moins
    12 min